AAIC 2022 | Targeting neuroinflammation: identifying new targets using transcriptomics

Niels Plath, PhD, Muna Therapeutics, Copenhagen, Denmark, gives an insight to the latest Alzheimer’s disease (AD) research from Muna Therapeutics. Their current research is focused on targeting microglia in the context of neuroinflammation, via TREM2 agonism and Kv1.3 blockade which are both developing quickly through in vitro/in vivo validation platforms. At the same time, the team are utilizing transcriptomics data to identify novel target candidates. Several differentially expressed gene clusters have been identified in Alzheimer’s disease using this system, some of which map onto biological pathways that have already been associated with neurodegeneration. These findings provide novel entry points into highly relevant biological processes, which may point towards new drug targets. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.